Safety and efficacy of transfemoral intrahepatic portosystemic shunt for portal hypertension: A single-center retrospective study

Table 3 Comparison of clinical effects

Index	TFIPS group, n = 19		TIPS group, n = 21		t/χ2		P value
	12 mo	24 mo	12 mo	24 mo	12 mo	24 mo	12 mo	24 mo
Child-Pugh score	5.45 ± 1.60	6.32 ± 1.60	6.45 ± 1.50	7.11 ± 1.60	0.042	0.061	0.852	0.813
MELD score	10.31 ± 1.44	11.52 ± 1.43	11.12 ± 1.55	11.14 ± 1.79	0.487	0.624	0.794	0.527
Blood ammonia	83.6 ± 39.4	87.3 ± 33.1	85.7 ± 23.4	88.2 ± 29.6	0.758	0.518	0.246	0.238
Variceal rebleeding, n (%)	1 (5.3)	1 (5.3)	1 (4.8)	2 (9.5)	0.005	0.261	0.942	0.609
RS, n	0	0	0	0	0	1	0	1
Shunt patency	18 (94.7)	18 (94.7)	20 (95.2)	19 (90.5)	0.005	0.261	0.942	0.609
HE, n (%)	4 (21.1)	5 (26.3)	4 (19.0)	6 (28.6)	0.025	0.025	0.874	0.873
grade of HE, n					0.107	0.166	0.948	0.573
I	2	2	1	2
II	1	2	2	3
III	1	1	1	1
IV	0	0	0	0
HM, n	0	0	0	0	0	1	0	1
Survival, n (%)	18 (94.7)	18 (94.7)	21(100)	20 (95.2)	0	0.001	1	0.981

MELD: Model for end-stage liver disease; RS: Refractory ascites; HE: Hepatic encephalopathy; HM: Hepatic myelopathy; TFIPS: Transfemoral intrahepatic portosystemic shunt; TIPS: Transjugular intrahepatic portosystemic shunt.